FDA approves Leqvio injection as a treatment and tolerated statin therapy for the patients who require additional lowering of low-density lipoprotein cholesterol commonly known as LDL-C. Leqvio injection works to reduce levels of LDL-C in the body, commonly known as “bad cholesterol.” Leqvio injection is approved at a 284 mg dose/drug as an initial under-the skin injection, a second dose at three months, and continued treatment once every six months after the point. Heterozygous familial holesterolemia (HEFH) is a rare disease, life-threatening condition. As a result, patients have extremely high levels of LDL-C in their body. Atherosclerotic cardiovascular disease (ASCVD) involves the buildup of cholesterol plaque in arteries near the heart. Common side effects seen of Leqvio injection (inclisiran) include injection site reaction, joint stiffness, urinary tract infection, diarrhea, bronchitis, pain in extremity, and difficulty breathing.
Morulaa is specialist in Medical device approval, We have provided high quality and professional services on medical devices, cosmetics, IVD, drugs etc. Stay updated on the latest medical device rules and subscribe to our website now if you’re planning your future market in India. If you have any enquiry on Medical device approval and registration, Contact admin@morulaa.com.
